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Abstract
In recent years, there has been an increasing interest in investigating the carcinogenic-
ity of mycotoxins in humans. This systematic review aims to provide an overview of
data linking exposure to different mycotoxins with human cancer risk. Publications
(2019 and earlier) of case–control or longitudinal cohort studies were identified in
PubMed and EMBASE. These articles were then screened by independent reviewers
and their quality was assessed according to the Newcastle–Ottawa scale. Animal,
cross-sectional, and molecular studies satisfied criteria for exclusion. In total, 14
articles were included: 13 case–control studies and 1 longitudinal cohort study.
Included articles focused on associations of mycotoxin exposure with primary liver,
breast, and cervical cancer. Overall, a positive association between the consumption
of aflatoxin-contaminated foods and primary liver cancer risk was verified. Two
case–control studies in Africa investigated the relationship between zearalenone and
its metabolites and breast cancer risk, though conflicting results were reported. Two
case–control studies investigated the association between hepatocellular carcinoma
and fumonisin B1 exposure, but no significant associations were observed. This
systematic review incorporates several clear observations of dose-dependent asso-
ciations between aflatoxins and liver cancer risk, in keeping with IARC Monograph
conclusions. Only few human epidemiological studies investigated the associations
between mycotoxin exposures and cancer risk. To close this gap, more in-depth
research is needed to unravel evidence for other common mycotoxins, such as
deoxynivalenol and ochratoxin A. The link between mycotoxin exposures and cancer
risk has mainly been established in experimental studies, and needs to be confirmed in
human epidemiological studies to support the evidence-based public health strategies.
KEYWORD S
aflatoxin, cancer, exposure, food, fumonisin, fungal metabolites, mycotoxins
Compr Rev Food Sci Food Saf. 2020;1–16. © 2020 Institute of Food Technologists® 1wileyonlinelibrary.com/journal/crf3
21 INTRODUCTION
Mycotoxins are fungal secondary metabolites that exert
adverse health effects on humans and animals through
primarily oral exposure. These fungi widely occur on agricul-
tural crops, such as wheat, maize (corn), and nuts, and their
derived food and feed products. In certain climatic conditions,
molds are capable of producing more than one mycotoxin,
and some mycotoxins are produced by more than one fungal
species (Zain, 2011). This consequently results in the coex-
posure to multiple mycotoxins and the risk of subsequent
associated adverse effects, including carcinogenicity. The
type of mycotoxin and the level and frequency of exposure
(acute or chronic) affect the manifestation of the disease, as
well as age, body mass index, gender, concomitant health
issues, and possible synergistic effects of other chemicals to
which the individual is exposed to (De Ruyck et al., 2015;
Peraica et al., 1999). Acute toxicity generally has a rapid
onset and an obvious toxic response, while chronic toxicity is
characterized by low-dose exposure over a long time-period,
which can ultimately result in malignant tumors and other
permanent detrimental effects (De Ruyck et al., 2015).
Most of the mycotoxins are easily absorbed from the
site of exposure, such as the gastrointestinal (i.e., dietary
consumption) or respiratory tract (i.e., inhalation dust), to the
circulatory system reaching vital, as the toxin is distributed
throughout the body (Adam et al., 2017). Mycotoxins
can enter human and animal cells and exert a spectrum
of effects, including permanent damage. Through natural
cellular processes of transcription and translation, these
mutations may manifest or even exacerbate deregulation
of cell growth (Adam et al., 2017). Several cellular pro-
cesses, including DNA replication and protein synthesis, are
affected by ochratoxin A (OTA) and deoxynivalenol (DON).
Moreover, aflatoxin B1 (AFB1) has been recognized for its
carcinogenicity, mostly through genotoxic effects, by the
World Health Organization’s (WHO) International Agency
for Research on Cancer (IARC) Monographs Program (De
Ruyck et al., 2015). Table 1 represents the mycotoxins
classified by the IARC Monograph evaluation program.
Many mycotoxins exhibit overlapping toxicities in ani-
mals, plants, and microorganisms. The individual or intrinsic
toxicity has been investigated for numerous mycotoxins,
usually in relation to acute pathologies (De Ruyck et al.,
2015). Among chronic coexposures to mycotoxins, complex
interactions have recently been suggested, possibly resulting
in additive or even synergistic effects (De Ruyck et al.,
2015). Despite the growing number of studies and evidence,
additional in-depth investigations are needed to confirm the
ability of each individual and/or combinations of mycotoxins
to induce cancer (Adam et al., 2017). The type and mecha-
nism of action of mycotoxins within the biological system
determines its role in causing cancer and contributes to other
adverse health effects (Adam et al., 2017). In the recent years,
there has been an increasing interest in the investigation
of mycotoxin-induced carcinogenicity and the underlying
mechanisms, using animal models and cultured cell systems.
In addition to animal and mechanistic studies, IARC Mono-
graphs evaluations (Table 1) put a strong emphasis on human
epidemiological studies for carcinogenicity classification
(IARC, 1993a, 2012). To investigate mycotoxin-mediated
cancer risk in humans, large-scale epidemiological studies
are warranted. The main purpose of this systematic review is
to summarize the current evidence regarding the relationship
between mycotoxins and cancer risk in humans.
2 MATERIALS AND METHODS
2.1 Data sources and search strategy
Searches of PubMed and EMBASE (from their commence-
ments to December 2019) were performed, comprising
keywords related to mycotoxins (“mycotoxins,” “ fungal
metabolites,” “aflatoxin,” “ochratoxin,” “ergot alkaloids,”
“patulin,” “fusarium,” “deoxynivalenol,” “diacetoxyscir-
penol,” “zearalenone,” “fusaric acid,” “sterigmatocystin,”
“Alternaria alternata pathotoxin TA,” “altertoxin,” “ten-
toxin,” “citrinin,” “beauvericin,” “mycophenolic acid,”
“enniatins,” and “phomopsin”) combined with “exposure,”
“neoplasms,” “cancer,” and “humans.”
MeSH and Emtree terms were used to build up a structured
search. To find additional articles, evidence tables and
references from earlier publications were examined.
Pubmed Syntax: (“mycotoxin”[All Fields] OR “afla-
toxin”[All Fields] OR “ochratoxin”[All Fields] OR “ergot
alkaloids”[All Fields] OR “patulin”[All Fields] OR “Fusar-
ium”[All Fields] OR “deoxynivalenol”[All Fields] OR
“diacetoxyscirpenol”[All Fields] OR “zearalenone”[All
Fields] OR “fusaric acid”[All Fields] OR “sterigmato-
cystin”[All Fields] OR “Alternaria alternata pathotoxin
TA”[All Fields] OR “altertoxin”[All Fields] OR “ten-
toxin”[All Fields] OR “citrinin”[All Fields] OR “beau-
vericin”[All Fields] OR “mycophenolic acid”[All Fields] OR
“enniatins”[All Fields] OR “phomopsin”[All Fields]) AND
(“exposure”[All Fields]) AND (“neoplasms”[All Fields] OR
“cancer”[All Fields]) AND “humans”[MeSH Terms].
2.2 Study selection
2.2.1 Inclusion criteria
Studies were only included if they investigated the link
between mycotoxin exposure and risks of one or more cancer
types in humans. Specifically, only cohort studies, and
3TABLE 1 Mycotoxins classified according to the IARC Monograph that identifies and evaluates environmental causes of cancer in humans
IARC classification (IARC,
2006) Mycotoxin (IARC, 2012) Publication year of IARC Monograph
Group 1: the agent is
carcinogenic to humans
AFB1, AFB2, AFG1,
AFG2, AFM1
2012 (IARC, 2019; IARC, 2012)
Group 2A: the agent is
probably carcinogenic to
humans
Group 2B: the argent is
possibly carcinogenic to
humans
OTA
FB1, FB2
STC
Fusarin C
1993 (IARC, 1993b)
2002 (IARC Monographs Priorities Group, 2019; IARC, 2002)
1987 (IARC, 1987a)
1993 (IARC, 1993a)
Group 3: the agent is not
classifiable as to its
carcinogenicity to humans
DON
ZEN
Fusarenone X
CIT
PAT
1993 (IARC, 1993a)
1993 (IARC, 1993a)
1993 (IARC, 1993a)
1987 (IARC, 1987b)
1987 (IARC, 1987b)
Group 4: the agent is probably
not carcinogenic to humans
Abbreviations: AFB1, aflatoxin B1; AFB2, aflatoxin B2; AFG1, aflatoxin G1; AFG2, aflatoxin G2; AFM1, aflatoxin M1; CIT, citrinin; DON, deoxynivalenol; FB1,
fumonisin B1; FB2, fumonisin B2; OTA, ochratoxin A; PAT, patulin; STC, sterigmatocystin; ZEN, zearalenone.
(nested) case–control studies were included. Only articles
originally published in English were included.
2.2.2 Exclusion criteria
The criteria for exclusion of studies were cross-sectional
studies, noncohort or noncase–control studies, molecular
studies (e.g., animal and cell line studies), and molecu-
lar patterns of carcinogenesis studies. Publications that
did not focus on the link between mycotoxin exposure
and cancer risk but only on mycotoxins or cancer were
excluded.
2.2.3 Type of outcome measurements
Original research on the risk of cancer associated with human
exposure to mycotoxins was systematically reviewed and
presented here to provide an update on current research in
this critical field.
2.3 Data collection and analysis
2.3.1 Selection of studies
Three investigators (L.C., C.R., and H.W.) independently
selected titles and abstracts from the bibliography retrieved
by the search strategy, according to the inclusion and exclu-
sion criteria. Selections from the search strategy were entered
in an EndNote library. Full text copies were then obtained
for studies that fulfilled the criteria. In case of disagreement
between the three investigators or when fulfillment to the
criteria was unclear, the opinion of the writing group was
requested to reach consensus. The study selection procedure
is summarized in Figure 1.
2.3.2 Quality of the articles
To analyze the quality of the articles, the Newcastle–Ottawa
scale (NOS) of quality assessment was used (Ottawa Hospital
Reseach Institute, n.d.). This assessment scale consists of
three categories (selection, comparability, and exposure);
therefore, each study was evaluated on three broad criteria:
(a) proper selection of study population, (b) comparability
of the study groups, and (c) ascertainment of the exposure
or outcome of interest. Each article could receive up to
four stars for selection, two stars for comparison, and three
stars for exposure. Table A1 presents an overview of the
Newcastle–Ottawa criteria used for the quality assessment of
case–control and cohort studies.
2.3.3 Types of mycotoxins and cancer
Mycotoxin exposure and specific cancer sites were consid-
ered.
2.3.4 Data extraction
The following parameters were extracted from the publica-
tions and included in the final article selection: length of
follow-up, potential confounders taken into account (e.g., age
and gender), study type, mycotoxin type, type of matrix, can-
cer site, location/duration of the study, range of exposure, and
analytical detection limit. Table 2 shows the final selection
of publications, detailing their characteristics of eligibility.
4F IGURE 1 Selection of studies for inclusion in
the systematic review
3 RESULTS
3.1 Study design and population
characteristics
A total of 14 articles were finally included in this systematic
review. A detailed overview of the different studies and their
study design and methods used is given in Table 2. Thirteen
studies were case–control studies, including three nested
case–control studies, and one study was a longitudinal cohort
study. The most frequently studied cancer was primary liver
cancer (PLC), followed by breast cancer.
Most of the studies were conducted in Asia (n = 11),
followed by Africa (n = 3). No comparable studies from
Europe were found that fulfilled the inclusion criteria.
Aflatoxins (AFs) were the mycotoxins most frequently
studied or observed, followed by fumonisin B1 (FB1) and
zearalenone (ZEN). Different exposure matrices were exam-
ined. The majority of the studies used blood, plasma, or serum
(n = 5), or urine (n = 5), followed by food (n = 2) or toenails
(n = 2) as exposure matrices. Other examined matrices were
feces (n = 1), liver tissue (n = 1), and dust (n = 1).
The years of publication ranged from 1982 to 2015, with
the majority (n = 8) published between 2000 and 2015.
The size of the study populations varied widely. One
article had a sample size of only 58 participants, eight articles
had a population ranging from 100 to 300, four studies used a
population size from 300 to 700, and one study included over
900 subjects. The largest number of subjects was studied in
the context of liver cancer (n = 1,102). All studies covered a
population ranging in age between 15 and 74 years.
Table 3 outlines the observed mycotoxins in the selected
studies and the different cancer types for which a relationship
has been investigated.
Ten studies examined the association between AF and
PLC. PLC was divided into hepatocellular carcinoma (HCC)
(n = 7) and cholangiocarcinoma (n = 1); two articles did not
further specify the type of PLC. In addition to AF, two arti-
cles investigated PLC, namely, HCC, in relation to the FB1
exposure. Three studies examined the carcinogenic effects of
ZEN: two with breast cancer and one with cervical cancer.
3.2 Study quality
The NOS was used to evaluate the quality of each article, as
described in Table 2. Overall scores ranged from 0 to 7. Some
articles did not give information on the participants nor had
an appropriate study design. Most of the articles scored well
for selection: five articles received four stars, five articles
had three stars, one article had two stars, and one article had
one star. Two publications scored zero for selection, mainly
due to the lack of information on the selection of controls;
however, it remained in the review material based on the
relevance of the cancer scope and study size.
5TA
B
L
E
2
C
h
ar
ac
te
ri
st
ic
s
o
f
th
e
el
ig
ib
le
st
u
d
ie
s
in
cl
u
d
ed
in
th
e
sy
st
em
at
ic
re
v
ie
w
№
So
ur
ce
Po
pu
-
lat
ion
St
ud
y
pe
rio
d
St
ud
y
ty
pe
Se
x
N
M
ea
n
ag
e
(𝝈
)
Ca
se
sC
on
t-
ro
ls
St
ud
y
du
ra
tio
n
Ex
po
su
re
M
T
LO
D;
LO
Q
M
at
rix
Ca
nc
er
sit
e(s
)
OR
s,
RR
s
Qu
ali
ty
of
th
ea
rti
cle
1
B
el
h
as
se
n
et
al
.
(2
0
1
5
)
T
u
n
is
ia
0
5
/2
0
1
2
–
1
0
/2
0
1
2
C
c
F
1
1
0
4
9
.9
(1
1
.0
)
6
9
4
1
6
m
o
n
th
s
n
/a
𝛼
-Z
A
L
0
.2
n
g
/m
L
;
0
.7
n
g
/m
L
U
ri
n
e
B
re
as
t
O
R
:
1
.5
4
S
el
ec
ti
o
n
:*
*
C
o
m
p
ar
ab
il
it
y
:*
E
x
p
o
su
re
:*
*
*
T
o
ta
l
N
O
S
sc
o
re
:
6
2
B
u
la
ta
o
-
Ja
y
m
e,
A
lm
er
o
,
C
as
tr
o
,
Ja
rd
el
ez
a,
an
d
S
al
am
at
(1
9
8
2
)
P
h
il
ip
p
in
es
n
/a
C
c
B (8
2
.2
%
M
)
1
8
0
1
5
-7
4
9
0
9
0
n
/a
D
ie
ta
ry
A
F
n
/a
U
ri
n
e
P
L
C
R
R
:
L
ig
h
tA
F
/M
o
d
er
at
eA
F
/
H
ea
v
y
A
F
:
1
/1
3
.9
/1
7
S
el
ec
ti
o
n
:*
*
*
C
o
m
p
ar
ab
il
it
y
:*
E
x
p
o
su
re
:*
*
T
o
ta
l
N
O
S
sc
o
re
:
6
3
C
h
ao
et
al
.
(1
9
9
4
)
S
in
g
ap
o
re
1
9
9
1
–
1
9
9
2
C
c
n
/a
4
8
1
n
/a
5
8
4
2
3
2
y
ea
rs
n
/a
A
F
n
/a
B
lo
o
d
an
d
li
v
er
P
L
C
:
H
C
C
n
/a
S
el
ec
ti
o
n
:
/
C
o
m
p
ar
ab
il
it
y
:
/ E
x
p
o
su
re
:
/
T
o
ta
l
N
O
S
sc
o
re
:
0
4
C
h
en
et
al
.
(2
0
1
3
)
C
h
in
a
1
9
8
2
–
2
0
1
2
L
o
n
g
it
u
d
in
al
co
h
o
rt
B (6
1
.7
%
M
)
6
5
2
2
1
-6
5
n
/a
n
/a
3
0
y
ea
rs
D
ie
ta
ry
A
F
n
/a
S
er
u
m
P
L
C
R
R
:
7
.3
(m
en
w
it
h
H
B
V
,
n
o
A
F
)
R
R
:
3
.4
(m
en
w
it
h
n
o
H
B
V
,
A
F
)
R
R
:
5
9
.4
(m
en
w
it
h
H
B
V
,
u
ri
n
ar
y
A
F
-
b
io
m
ar
k
er
s)
S
el
ec
ti
o
n
:
/
C
o
m
p
ar
ab
il
it
y
:*
E
x
p
o
su
re
:
/
T
o
ta
l
N
O
S
sc
o
re
:
1
5
L
ai
et
al
.
(2
0
1
4
)
C
h
in
a
1
0
/2
0
1
3
–
0
3
/2
0
1
4
C
c
B
2
1
8
4
0
.3
8
(9
.3
2
)
6
8
1
5
0
6
m
o
n
th
s
E
n
v
ir
o
n
m
en
ta
lA
F
n
/a
D
u
st
an
d
se
ru
m
P
L
C
:
H
C
C
O
R
:
5
.2
4
S
el
ec
ti
o
n
:*
*
*
*
C
o
m
p
ar
ab
il
it
y
:*
*
E
x
p
o
su
re
:*
T
o
ta
l
N
O
S
sc
o
re
:
7
6
O
m
er
et
al
.
(1
9
9
8
)
S
u
d
an
0
5
/1
9
9
5
–
1
1
/1
9
9
5
C
c
n
/a
5
8
n
/a
2
4
3
4
7
m
o
n
th
s
n
/a
A
F
n
/a
F
o
o
d
P
L
C
:
H
C
C
O
R
:
7
.5
S
el
ec
ti
o
n
:*
*
*
C
o
m
p
ar
ab
il
it
y
:*
*
E
x
p
o
su
re
:*
T
o
ta
l
N
O
S
sc
o
re
:
6
7
P
ar
k
in
et
al
.
(1
9
9
1
)
T
h
ai
la
n
d
1
9
8
7
–
1
9
8
8
C
c
B (6
8
.9
%
M
)
2
0
6
5
4
.7
5
(1
1
.9
)
1
0
3
1
0
3
1
y
ea
r
D
ie
ta
ry
A
F
n
/a
B
lo
o
d
an
d
fe
ce
s
P
L
C
:
C
h
o
la
n
g
io
-
ca
rc
in
o
m
a
O
R
:
1
.4
S
el
ec
ti
o
n
:*
*
*
C
o
m
p
ar
ab
il
it
y
:*
*
E
x
p
o
su
re
:*
T
o
ta
l
N
O
S
sc
o
re
:
6
(C
o
n
ti
n
u
es
)
6TA
B
L
E
2
(C
o
n
ti
n
u
ed
)
№
So
ur
ce
Po
pu
-
lat
ion
St
ud
y
pe
rio
d
St
ud
y
ty
pe
Se
x
N
M
ea
n
ag
e
(𝝈
)
Ca
se
sC
on
t-
ro
ls
St
ud
y
du
ra
tio
n
Ex
po
su
re
M
T
LO
D;
LO
Q
M
at
rix
Ca
nc
er
sit
e(s
)
OR
s,
RR
s
Qu
ali
ty
of
th
ea
rti
cle
8
P
er
ss
o
n
et
al
.
(2
0
1
2
)
C
h
in
a
0
1
/1
9
9
3
–
0
9
/2
0
0
0
N
es
te
d
cc
B (9
1
.8
%
M
)
5
5
1
4
5
(8
.8
)
2
7
1
2
8
0
7
y
ea
rs
,
8
m
o
n
th
s
n
/a
F
B
1
6
p
g
/L
;
2
0
p
g
/L
T
o
en
ai
ls
P
L
C
:
H
C
C
O
R
:
1
.1
S
el
ec
ti
o
n
:*
*
*
*
C
o
m
p
ar
ab
il
it
y
:*
*
E
x
p
o
su
re
:*
T
o
ta
l
N
O
S
sc
o
re
:
7
9
P
er
ss
o
n
et
al
.
(2
0
1
2
)
C
h
in
a
0
5
/1
9
9
1
–
0
5
/2
0
0
1
N
es
te
d
cc
B (7
4
.4
%
M
)
2
1
9
5
6
(7
.8
)
7
2
1
4
7
1
0
y
ea
rs
n
/a
F
B
1
6
p
g
/L
;
2
0
p
g
/L
T
o
en
ai
ls
P
L
C
:
H
C
C
O
R
:
1
.4
7
S
el
ec
ti
o
n
:*
*
*
*
C
o
m
p
ar
ab
il
it
y
:*
*
E
x
p
o
su
re
:*
T
o
ta
l
N
O
S
sc
o
re
:
7
1
0
P
il
la
y
et
al
.
(2
0
0
2
)
S
o
u
th
A
fr
ic
a
n
/a
C
c
F
1
0
6
n
/a
8
2
2
4
n
/a
n
/a
Z
E
N
2
5
n
g
/m
L
S
er
u
m
B
re
as
t,
ce
rv
ix
n
/a
S
el
ec
ti
o
n
:*
C
o
m
p
ar
ab
il
it
y
:*
E
x
p
o
su
re
:
/
T
o
ta
l
N
O
S
sc
o
re
:
2
1
1
W
an
g
et
al
.
(1
9
9
6
)
T
ai
w
an
0
2
/1
9
9
1
–
0
6
/1
9
9
5
C
c
B (8
9
.5
%
M
)
2
7
6
n
/a
5
6
2
2
0
4
y
ea
rs
,
5
m
o
n
th
s
E
n
v
ir
o
n
m
en
ta
lA
F
0
.0
1
fm
/𝜇
g
al
b
u
m
in
B
lo
o
d
an
d
u
ri
n
e
P
L
C
:
H
C
C
O
R
:
7
.2
S
el
ec
ti
o
n
:*
*
*
C
o
m
p
ar
ab
il
it
y
:*
*
E
x
p
o
su
re
:*
T
o
ta
l
N
O
S
sc
o
re
:
6
1
2
W
u
et
al
.
(2
0
0
8
)
T
ai
w
an
0
2
/1
9
9
1
–
0
6
/2
0
0
1
N
es
te
d
cc
B
3
6
4
n
/a
7
4
2
9
0
1
0
y
ea
rs
,
5
m
o
n
th
s
E
n
v
ir
o
n
m
en
ta
lA
F
B
1
0
.2
n
g
/m
L
U
ri
n
e
P
L
C
:
H
C
C
O
R
:
7
.5
S
el
ec
ti
o
n
:*
*
*
*
C
o
m
p
ar
ab
il
it
y
:*
*
E
x
p
o
su
re
:*
T
o
ta
l
N
O
S
sc
o
re
:
7
1
3
W
u
et
al
.
(2
0
0
9
)
T
ai
w
an
0
2
/1
9
9
1
–
0
6
/2
0
0
4
cc
B (8
3
.3
%
M
)
1
.1
0
2
n
/a
1
9
8
9
0
4
1
3
y
ea
rs
,
5
m
o
n
th
s
E
n
v
ir
o
n
m
en
ta
lA
F
B
1
n
/a
U
ri
n
e
P
L
C
:
H
C
C
O
R
:
5
.5
S
el
ec
ti
o
n
:*
*
*
*
C
o
m
p
ar
ab
il
it
y
:*
*
E
x
p
o
su
re
:*
T
o
ta
l
N
O
S
sc
o
re
:
7
1
4
Z
h
an
g
,
W
an
g
,
H
an
,
&
Z
h
u
an
g
(1
9
9
8
)
C
h
in
a
0
1
/1
9
9
4
–
1
0
/1
9
9
5
cc
B (8
8
.0
%
M
)
2
6
7
5
2
(1
2
.6
)
1
5
2
1
1
5
1
y
ea
r,
1
0
m
o
n
th
s
D
ie
ta
ry
A
F
n
/a
F
o
o
d
P
L
C
:
H
C
C
O
R
:
1
6
.4
4
S
el
ec
ti
o
n
:*
*
*
C
o
m
p
ar
ab
il
it
y
:*
*
E
x
p
o
su
re
:*
T
o
ta
l
N
O
S
sc
o
re
:
6
A
b
b
re
v
ia
ti
o
n
s:
A
F
B
1
,
af
la
to
x
in
B
1
;
A
F
,
af
la
to
x
in
s;
B
,
b
o
th
se
x
es
;
cc
,
ca
se
–
co
n
tr
o
l;
F
,
fe
m
al
e;
F
B
1
,
fu
m
o
n
is
in
B
1
;
H
C
C
,
h
ep
at
o
ce
ll
u
la
r
ca
rc
in
o
m
a;
L
O
D
,
li
m
it
o
f
d
et
ec
ti
o
n
;
L
O
Q
,
li
m
it
o
f
q
u
an
ti
fi
ca
ti
o
n
;
M
,
m
al
e;
M
T
,
m
y
co
to
x
in
;
N
O
S
,
N
ew
ca
st
le
–
O
tt
aw
a
sc
al
e;
n
/a
,
n
o
t
av
ai
la
b
le
;
O
R
,
o
d
d
s
ra
ti
o
;
P
L
C
,
p
ri
m
ar
y
li
v
er
ca
n
ce
r;
R
R
,
re
la
ti
v
e
ri
sk
;
Z
E
N
,
ze
ar
al
en
o
n
e;
𝛼
-Z
A
L
,
𝛼
-z
ea
ra
la
n
o
l;
P
o
in
ts
as
si
g
n
ed
fo
r
th
e
N
O
S
sc
o
re
w
er
e
p
re
se
n
te
d
as
st
ar
s
(*
).
O
n
e
st
ar
st
an
d
s
fo
r
o
n
e
p
o
in
t.
7TABLE 3 Reviewed mycotoxins and possible links with cancer researched in this study, linked with the cancer subtypes and amount of articles
Mycotoxin
Link with the
following cancer(s) Cancer subtypes
Aflatoxins Primary liver cancer 7 - hepatocellular carcinoma1 - cholangiocarcinoma2 - no type specified
Fumonisin
B1
Primary liver cancer 2 - hepatocellular carcinoma
Zearalenone Breast cancer 2
Zearalenone Cervical cancer 1
For comparability, nine articles scored the maximum of
two stars, while four articles received one star. One publica-
tion did not obtain any score for comparability. For the third
category, exposure, most of the articles had only one star;
only one publication had three stars and one received two
stars. Low scores on exposure were mostly caused by the con-
firmation of exposure, which was performed by a nonblinded
interview, and did not mention the nonresponse rate.
3.3 Overall significant findings
Ten studies investigated the associations between AF and
liver cancer risk, of which nine suggested a positive, dose-
dependent association between the consumption of AF and
the risk of developing PLC. On the other hand, only one
single article did not find an association between liver cancer
and AF intake, hepatitis B infection, and a particular dietary
pattern (Parkin et al., 1991).
Two case–control studies in Africa investigated the
associations between ZEN and its metabolites, namely,
𝛼-zearalenol (𝛼-ZEL), 𝛽-zearalenol (𝛽-ZEL), 𝛼-zearalanol
(𝛼-ZAL), 𝛽-zearalanol (𝛽-ZAL), and zearalanone (ZAN),
with breast cancer risk. Conflicting results were found,
although, the examined biological matrices may not be
directly comparable, as one study examined blood and the
other urine. Only one article investigated the cervical cancer
risk in relation to ZEN exposure. No results were found to
suggest a causal relationship between the presence of ZEN in
blood and cervical cancer in the study population.
Finally, two studies using a case–control design examined
the association between HCC and FB1 exposure. No statis-
tically significant associations were found between FB1 and
HCC (Persson et al., 2012).
4 DISCUSSION
4.1 Liver cancer
Most publications in this systematic review examined the
association between AF and liver cancer. AF, namely, AFB1,
aflatoxin B2 (AFB2), aflatoxin G1 (AFG1), aflatoxin G2
(AFG2), and aflatoxin M1 (AFM1), are the only myco-
toxins categorized as Group 1 carcinogens by the IARC
Monographs (IARC, 2012; IARC, 2019a). Based on the
report of the IARC’s Monographs Priorities Group, AFs are
annotated as medium priority agents for future evaluation
by the IARC Monographs with respect to additional cancer
sites (IARC, 2019). The included studies confirmed the
association between AF-exposure and increased liver cancer
risk. These findings further support the World Cancer
Research Fund (WCRF)’s conclusions of strong evidence
linking AF-contaminated foods with liver cancer risk
(Forner et al., 2015)
Experimental animal studies observed carcinogenic effects
of AFB1 and AFG1, as opposed to AFB2 and AFG2, where
inadequate evidence was found for their carcinogenicity
(Baertschi et al., 1989). The liver is the primary target organ
for AF with observed liver damage occurring when poultry,
fish, rodents, and nonhuman primates were fed with AFB1.
On a molecular level, AFB1 induces genetic instability,
point mutations, and genetic recombination during mitosis
in mammalian cells. Moreover, there is strong evidence that
AFB1-induced mutagenicity is due to a direct genotoxic
mode of action (IARC, 2012; Knutsen et al., 2018; Zain
et al., 2011). AFB1 is metabolized, through oxidation by
cytochrome P450 (CYP450), to aflatoxin-8,9-epoxide, which
is unstable and highly reactive, and can bind to DNA or
proteins (e.g., albumin) (Adam et al., 2017; Bbosa et al.,
2013; Eaton & Groopman, 1994; FAO/WHO Expert Com-
mittee on Food Additives, 2017; He et al., 2006). Upon
reactions with DNA molecules, aflatoxin-8,9-epoxide forms
the aflatoxin-N7-guanine-adduct, which during DNA repli-
cation causes G:C to T:A transversion mutations (McCull
ough & Lloyd, 2019;Huang et al., 2017). If these mutations
occur in important cancer-related genes (oncogenes or tumor
suppressor genes), they can lead to the increased proliferation
of abnormal cells, ultimately resulting in the development
of cancer.
AFs have been linked to HCC incidence in low- and
middle income countries, through the consumption of
subsistence-farmed agricultural crops (Turner et al., 2002;
IARC, 2015). In contrast to the majority of findings from this
systematic review, one reviewed study reported no evidence
for an association of liver cancer with AF intake, hepatitis
8B infection, or any dietary pattern (Parkin et al., 1991). The
study focused on cholangiocarcinoma, a malignant tumor
in the bile ducts, whereas the association of AF with liver
cancer is usually studied in the context of HCC (Forner
et al., 2015). This suggests that a diverse causation for
different subtypes of liver cancer, that is, unspecified PLC,
HCC, and cholangiocarcinoma, could explain the hetero-
geneity among study results (Forner et al., 2015). There are
inadequate high-quality studies, supporting the contradictory
result of the described study, which is why these results need
to be interpreted with caution (Parkin et al., 1991).
Articles included in the review corrected their analyses by
using different confounders. According to the literature and
an overview provided by the WCRF, factors influencing liver
cancer risk include overweight or obesity, alcohol consump-
tion, fish, or other AF-contaminated foods, coffee drinking,
physical activity, liver cirrhosis, chronic viral hepatitis B/C,
chronic use of oral contraceptives containing high levels of
estroprogestatives, or smoking, in human epidemiological
studies. The different use of confounders can critically
influence the result obtained by human epidemiological
studies (Forner et al., 2015).
Most of the studies included used blood as an exposure
matrix and adjusted for smoking status, but only some studies
adjusted for hepatitis B virus (HBV) and hepatitis C virus
(HCV) as confounders or effect modifiers (Forner et al.,
2015). The Western Pacific and African Regions have the
highest hepatitis B prevalence, with 6.2% and 6.1% of the
adult population infected, respectively. Three percent (3.3%)
of the general population of the WHO-delineated Eastern
Mediterranean is infected, followed by 2.0% of South-East
Asia and 1.6% of the European Region. Only 0.7% of the
WHO Region of the Americas is infected (Parkin et al., 2018;
World Health Organisation, 2017). HBV and HCV infections
account for the majority of cirrhosis and PLC throughout
most of the world (Perz et al., 2006). The synergistic effect
of HBV infection and AF-exposure might be explained by a
virus-induced increase in CYP450, which converts AF to its
reactive metabolite (Forner et al., 2015; Hernandez-Vargas
et al., 2015).
No statistically significant association was reported in the
two included case–control studies examining the association
between HCC and FB1 exposure. FB1 (IARC Group 2B) has
the potential to alter protein synthesis, and DNA synthesis
can be inhibited by higher concentrations in vitro in intestinal
cells (IARC, 2002; Kouadio et al., 2005; Rheeder et al.,
2002). An animal bioassay in rats (n = 25) confirmed the
hepatocarcinogenicity and hepatotoxicity of FB1 (Adam
et al., 2017; Gelderblom et al., 1991; Howard et al., 2001).
This finding is not yet confirmed in humans. A high evalu-
ation priority is recommended for FB1 because substantial
new information has become available since the previous
IARC Monographs evaluation (IARC, 2019). Evidence has
been presented for the inhibition of ceramide synthase in
people in Guatemala who consume corn-based foods with
a high FB1 content (Riley et al., 2015). It coincides with a
high incidence of liver cancer in individuals from this region,
although this is confounded by the presence of AFB1 (Torres
et al., 2015). Recent work further demonstrated that urinary
FB1 may be used to assess ongoing exposure to FB1 in
population-based studies. The improved exposure assessment
may increase the power of current and future epidemiological
studies to uncover relationships between FB1 exposure and
the development of preneoplastic lesions and/or cancer (Riley
et al., 2015; Torres et al., 2015). Furthermore, an elevation of
phosphorylated sphingoid bases in mouse embryonic fibrob-
lasts treated with FB1 has been associated with decreased
histone deacetylase activity and an increased acetylation of
histone lysines (Gardner et al., 2016; IARC, 2019b).
Besides the more common biological matrices, two studies
from China incorporated by this systematic review used
toenails as an exposure matrix (Persson et al., 2012). Toenails
have not been generally validated as a reliable matrix for
exposure assessment of FB1, and no other studies have
investigated the half-life of FB1 in nails, or the association
between measurable FB1 in nails and HCC. Inhibition of
ceramide synthase by exposure to FB results in increased sph-
ingolipid levels in serum, which can be used as a biomarker
of exposure (Desai et al., 2002; Persson et al., 2012). Due
to the lack of validated FB1 biomarkers of exposure and
based on rodent models, an allometrically projected serum
half-life of 128 min in humans, there have been few human
studies to date investigating the relationship between FB1 and
HCC (Delongchamp & Young, 2001; Persson et al., 2012;
Riley et al., 2012; Shephard et al., 2007). Recent human
urinary analyses of fumonisins identified FB1 as the most
prevalent form, ahead of FB2 and fumonisin B3 (FB3) (Vidal
et al., 2018). Studies in rodents and laboratory primates
showed that FB1 levels could be observed in hair after
exposure (Sewram et al., 2001), and may be a useful alter-
native for human exposure assessment (Persson et al., 2012;
Sewram et al., 2003).
4.2 Breast cancer
Two publications that investigated the association between
ZEN and breast cancer, both conducted in Africa, gave
conflicting results (Belhassen et al., 2015; Pillay et al., 2002).
One study in North-Africa (Tunisia) investigated the link
between urinary ZEN concentrations and breast cancer risk.
The results suggested a possible role for 𝛼-ZAL in breast
cancer development (Belhassen et al., 2015). 𝛼-ZAL can
originate from ZEN-metabolism or dietary consumption,
which is not yet a thoroughly characterized vector, as 𝛼-ZAL
can be found in meat when used as a growth promoter for
cattle (Stephany et al., 2009). Its diastereomers 𝛽-ZAL and
9ZAN are the metabolites of 𝛼-ZAL after ingestion by humans.
In addition, 𝛼-ZAL can be conjugated with glucuronic or
sulfonic acid (Belhassen et al., 2015). ZEN shares structural
similarity with the hormone 17𝛽-estradiol, thereby exerting
affinity to estrogen receptors, which can affect the fertility
in both humans and livestock (Adam et al., 2017). Different
estrogenic potencies were observed in vivo for ZEN and its
metabolites. To account for these differences, molar potency
factors relative to ZEN (relative potency factors, RPFs) were
calculated and applied to exposure estimates of the respective
ZEN-metabolites. RPFs were given on a molar basis for ZEN
(reference 1.0) and its metabolites as proposed by the EFSA
CONTAM Panel, with 𝛼-ZAL RPF 4.0, and 𝛼-zearalenol
(𝛼-ZEL) up to RPF 60 (Knutsen et al., 2017). These findings
further support the idea that ZEN and its metabolites may
play a role in reproductive organ cancer in both humans and
animals (Adam et al., 2017; Pillay et al., 2002). ZEN was also
found to be carcinogenic in mice, causing hepatocellular ade-
nomas and pituitary tumors (Pfohl-Leszkowicz et al., 1995;
National Toxicology Program, 1982; Eriksen et al., 1998).
Additional epidemiological studies with reliable exposure
assessment are required to confirm its potential carcinogenic-
ity in humans (Eriksen et al., 1998). However, the presence
of mycotoxin biomarkers in blood did not indicate a causal
relationship between exposure to these mycoestrogens and
breast cancer in a study in South-Africa (Pillay et al., 2002).
4.3 Cervical cancer
One epidemiological study in South-Africa investigated the
relationship between ZEN and cervical cancer but reported
no association (Pillay et al., 2002). Nevertheless, caution is
required when interpreting these results, as the NOS score of
the article is only 2, out of 9 stars that could be obtained. One
star was given in the category for proper selection of study
population and one in the category for comparability of the
study groups (Table 2). Hence, it could be hypothesized that
ZEN is involved in causing cancer of genitalia in humans,
since ZEN exerts estrogenic activity in many animal species,
and forms DNA adducts in genitalia of mice, rats, and
domestic animals, such as horses (Eriksen et al., 1998; Pillay
et al., 2002). Therefore, more high-quality research needs to
be undertaken to specifically unravel the association between
ZEN and cervical cancer.
4.4 Strengths and limitations of the
systematic review
This structured systematic review of mycotoxin exposure and
human cancer risk is the first of its kind in epidemiology.
PubMed and EMBASE were both comprehensive queried,
and the article selection was performed by three independent
reviewers. Finally, the quality of the articles was scaled using
the NOS of quality assessment.
However, this systematic review was prone to some limi-
tations. First, the comparability of study results was limited
because of differences in choice of biological matrix used for
exposure assessments, the study population demographics,
regionality, and each study’s approach to confounding fac-
tors. Second, the data extraction was not done in duplicate.
Finally, the quality of the studies included was considered
relatively limited. The studies evaluating the risk of liver
cancer were mainly assessed as good quality. Nevertheless,
2 out of the 12 studies on liver cancer were of low quality,
for example, Chao et al. (1994) did not report LOD/LOQ and
OR/RR-values. The two breast cancer studies had contrasting
results and quality scores, whereas the single investigation
into cervical cancer risk was of low quality. The deductions
and conclusions of some of these studies can, therefore, be
questioned and may warrant reinvestigation.
4.5 Implications for future research and
perspectives
Most studies investigating the associations between myco-
toxins exposures and cancer risk have focused on AF, while
the majority of mycotoxins (e.g., DON, citrinin [CIT],
patulin [PAT], ZEN, T-2 toxin [T-2], nivalenol [NIV],
and fusarenon-X [FUX]) are classified as IARC Group 3
compounds due to lacking information from both animal
and human carcinogenicity. For FB1, OTA, and STC (Group
2B), sufficient evidence of carcinogenicity in experimental
animal studies exists, but inadequate data on humans (IARC,
2012). Overall, these studies highlight the need for additional
high-quality animal and human studies to clarify their
contribution to cancer development. Moreover, the influence
and causative character of (emerging) mycotoxins needs to
be investigated with respect to additional cancer sites.
To date, no human epidemiological studies have reliably
confirmed the involvement of mycotoxins, except AFs, in
cancer development. This is reflected in the findings of the
IARC Monograph evaluations (Table 1) (IARC, 1993a 2012).
Consequently, there is clearly an urgent demand for more
human epidemiological studies. In addition, the currently
available literature is based on limited sample sizes and
variable study designs, which lower their overall quality and
complicates the comparison of published results. To tackle
this issue, comprehensively designed, large-scale prospective
cohort studies should be considered as one of the most
reliable and promising avenues for future research.
The countries with the highest incidence of cancer are
found in Oceania, Europe, and North-America (World
Cancer Research Fund, n.d.). This review did not cover any
studies investigating the associations between mycotoxin
exposures and cancer risk on these continents. Future studies,
10
particularly case–control studies, are therefore recommended
in these three continents that remain under-represented in the
literature of the field.
More research on reliable exposure matrices, methods
of exposure assessment, validated biomarkers of exposure
and effect, and their toxicokinetics needs to be undertaken.
Currently, only human biomarkers for AF and DON have
been validated (Ayelign et al., 2017; Mengelers et al., 2019;
Vidal, Claeys et al. 2018; Vidal et al., 2018). Prior studies
have noted the importance of multiple days of weighted diet
records to provide an optimal assessment of dietary factors
(Yuan et al., 2018). However, aggregation and heterogeneity
of mycotoxin patterns in agricultural products are common-
place, which effectively leads to unpredictable mixtures of
possible mycotoxin contamination in foods (Turner et al.,
2012). A recent study assessed multimycotoxin exposure by
24-hr dietary recalls and biological fluid sampling in a multi-
center European validation study. Multimycotoxin exposures,
calculated by intersecting quantities of consumed foods with
representative contaminant levels, indicated a probability of
exposure, which may be valid over a period contemporary to
the contamination data. Comparatively, the use of biological
sampling to assess mycotoxin dietary exposure enables far
higher resolution exposure assessments at the individual level,
though only within a short time window around the moment
of sample collection. Therefore, future research should further
invest in optimizing the assessments of mycotoxin exposures
for epidemiological investigations (De Ruyck et al., 2020).
So far, the few studies investigating the potential effects
of mycotoxin exposures on cancer risk focused on exposures
of single mycotoxins and their acute health effects; however,
in vivo studies using farm animals illustrated a complex set
of possible synergistic, additive, subadditive, or antagonistic
effects on animal health when mycotoxin mixtures were
administered (Bensassi et al., 2014; De Ruyck et al., 2015;
Grenier et al., 2011; Speijers et al., 2004). When chronically
exposed to multiple mycotoxins, complex interactions may
lead to any number of the aforementioned effects (Bensassi
et al., 2014; De Ruyck et al., 2015; Grenier et al., 2011). For
example, CIT acts synergistically with OTA on the kidneys
of single comb White Leghorn pullets (Glahn et al., 1988;
Speijers et al., 2004). Furthermore, when rats are exposed to
ZEN and other mycotoxins, simultaneously antagonistic toxic
effects have been reported in the liver and kidneys (Bensassi
et al., 2014; De Ruyck et al., 2015; Halabi et al., 1998). After
coexposure to ZEN and OTA in animals, it was noticed that
OTA-induced kidney damage was further antagonized by the
coexposure (Grenier et al., 2011). Finally, in contrast to the
individual exposures, either additive or antagonistic effects
on serum immunoglobulins were observed after coexposure
of mice to ZEN and DON (Forsell et al., 1986).
To date, several European regulations and recom-
mendations have been published to minimize mycotoxin
concentrations allowed in food and feed (The Commission
of the European Communities, 2006; Zain et al., 2011).
However, only individual exposures are taken into account
for these regulations. The complex dynamics of risks arising
from coexposure to multiple mycotoxins (or even other con-
taminants) are still a convoluted matter (Steinkellner et al.,
2019). Hence, further research investigating the potential
effect of mycotoxin coexposures on cancer risk is needed to
facilitate more targeted prevention strategies.
5 CONCLUSIONS
This systematic literature review of epidemiological studies
assessing the relationship between mycotoxin exposure and
cancer risk confirmed associations between AF and liver
cancer risk in humans, building on previously published
IARC Monograph evaluations. Few human studies have
specifically addressed the associations between mycotoxin
exposures and cancer risk, even though ample evidence
exists linking these mycotoxins to negative health effects by a
range of mechanisms, including genotoxicity. Well-designed
prospective cohort studies represent an important strategy
to address potential causal associations and ensure the
quality of the collected data, which appears to be a major
caveat of existing studies. Additionally, many emerging
mycotoxins remain generally uninvestigated with respect to
health outcomes at all, and this too requires urgent attention,
particularly in the real-world contexts of both highly variable
and highly parallel exposures. Mycotoxins are understood
to be ubiquitously present in agriculture, and may be
chronically consumed by large majorities of human popula-
tions all around the world, while having demonstrated myriad
toxic capabilities. Yet, even the tools of assessment used
for estimating mycotoxin exposure, such as dietary intake
assessments or biological sampling, do themselves require
further investigation and validation. Finally, to strengthen
the evidence calling for implementation of relevant public
health strategies, the latest human epidemiological as well
as experimental studies must be integrated with current legal
regulations and recommendations as a high priority.
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APPENDIX
TABLE A1 Newcastle–Ottawa criteria used for quality assessment
Case–control studies Cohort studies
Selection Proper selection of study population Proper selection of study population
1 Case definition adequate Representative of exposed cohort
2 Representativeness of the cases Selection of the nonexposed cohort
3 Selection of controls Ascertainment of exposure
4 Definition of controls Demonstration that outcome of interest was not present
at start of the study
Comparability Comparability of the study groups Comparability of cohorts on the basis of the design
or analysis
5 Studies that controlled for the most important factor Studies that controlled for the most important factor
6 Studies that controlled for any additional factor Studies that controlled for any additional factor
Exposure Ascertainment of the exposure or outcome of interest Ascertainment of the exposure or outcome of interest
7 Ascertainment of exposure Assessment of outcome
8 Same method of ascertainment for cases and controls Assessment of follow-up duration in terms of outcomes
9 Nonresponse rate Adequate follow-up of cohorts
